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A past history of clinical Lyme borreliosis and the 6-month incidence of clinical and asymp-
tomatic Lyme borreliosis was studied prospectively in a high-risk population. In the spring, blood
samples were drawn from 950 Swiss orienteers, who also answered a questionnaire. IgG anti-
Borreliaburgdorferi antibodies were detected by ELISA. Positive IgG antibodies were seen in
248 (26.1%), in contrast to 3.9%-6.0% in two groups of controls (n = 101). Of the orienteers,
1.9%-3.1% had a past history of definite or probable clinical Lyme borreliosis. Six months later
a second blood sample was obtained from 755 participants, 558 (73.9%) of whom were seronega-
tive initially; 45 (8.1%) had seroconverted from negative to positive. Only 1 (2.2%) developed
clinical Lyme borreliosis, Among all participants, the 6-month incidence of clinical Lyme bor-
reliosis was 0.8% (6/755) but was much higher (8.1%) for asymptomatic seroconversion (45/558).
In conclusion, positive Lyme serology was common in Swiss orienteers, but clinical disease oc-
curred infrequently.
Lyme disease, now often called Lyme borreliosis (LB), may
affect the skin, heart, joints, and nervous system [1-6]. Neu-
rologic, cardiologic, and rheumatologic manifestations such
as meningoencephalitis, neuropathy, atrioventricular nodal
block, myocarditis, and arthritis may follow in a few weeks
to months after erythema migrans (EM). This skin lesion,
although characteristic, is by no means an obligatory sign of
LB; it was found in only 41%-61% of patients with the dis-
ease [7, 8]. Arthritis typically is oligoarticular and recurrent
but may become chronic and erosive; it predominantly in-
volves the knee joints [3, 9].
LB is caused by the bite of ticks infected with the spirochete
Borrelia burgdorferi [10, 11]. The ticks that can transmit dis-
ease are part of the Ixodes ricinus complex. The discovery
of the spirochete led to serology as an aid in establishing the
diagnosis of LB, especially in the absence of EM [12].
In Europe the disorder seems to have a wide and constant
distribution [13]. In contrast, in the United States LB may
have been confined to three enzootic areas (northeast coast,
midwest, California), but cases appear to be increasing and
infection to be spreading to new areas. Recognition may also
account for some of the apparent increase. LB has now been
reported from 35 states.
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In Long Island, New York, the incidence ofLB was found
to be considerably higher than previously recognized [14].
Some patients showed inapparent seroconversion after infec-
tion. The estimated ratio of apparent to inapparent infection
was 1:1 in a study in Great Island, Massachusetts [8].
To assess the usefulness of Lyme serology as a diagnostic
tool, it would be important to know not only the sensitivity
and specificity of the test but also its predictive value. This
would imply knowledge about the prevalence and incidence
of clinical LB and the ratio of apparent to inapparent infec-
tions in populations where the test is applied.
We studied past history of clinical LB and frequency of posi-
tive Lyme serology in a population at risk and the frequency
of LB manifestations and seroconversion during 6 months of
follow-up.
Methods
Orienteers from all parts of Switzerland were invited to partici-
pate in the study. Orienteers, using map and compass, run competi-
tively through rough brushy terrain, the preferred habitat of I. ricinus.
Often running in short pants and sport shirts, they are at risk of be-
ing bitten by ticks. Orienteers usually exercise regularly in the forests
close to their homes. In addition, they participate every year in na-
tional competitions held in spring and autumn in various brushy
regions of Switzerland. In this country the infection rate of I. rici-
nus with B. burgdorferi ranges from 5 % to 34% [15].
Study group. Blood (10 ml) was obtained by venipuncture from
the participants of the 1986 spring competitions. Participants were
also asked to complete, on site, a questionnaire about exposure to
ticks and possible manifestations of LB. The following autumn, a
second blood sample was taken, and again a questionnaire was given
to the participants. Posters showing photographs of a typical exam-
ple of EM and of a tick attached to normal skin were shown to all
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Results
Table 1. History of tick exposure related to prevalence of IgG
anti-Borrelia antibodies (ELISA).
Responders. Of a total of 1294 participants in several
spring competitions, 964 agreed to enter the study (response
rate, 74.4%). Of them, 617 (64%) were male and 347 fe-
male. The mean age (±SD) of the responders was 31 ± 14
years (range, 10-74). In the fall, a second serum sample was
obtained from 755 (78.3 %) of the 964 participants.
Exposure rate. Most (78%) of the 964 persons who en-
tered the study reported at least one tick bite (table 1). There
obtained was used as reference for study sera. The optical density
(OD) of each sample was marked on this line and the result was
expressed as the logarithm of the diluted positive test serum. (Note
that low log-dilution values correspond with lesser dilution of the
positive test serum and therefore represent high anti-Borrelia anti-
body levels, whereas high log-dilution values reflect low antibody
levels.)
Each sample was tested in duplicate, and the mean value was cal-
culated. If both values for one sample differed by >10%, the test
was repeated. The second sample for each individual was tested "-'6
months after the first sample.
In the absence of a reference standard, the positive cutoff point
for IgG antibodies was defined as a log dilution of~ 3.74correspond-
ing to 2 SD below the mean log dilution of the 51 sera of the people
living at high altitude. This implies that statistically "-'2.5 % of sup-
posedly unexposed people might be expected to show false-positive
test results (type I error). Taking this cutoff point, the sensitivity
of the serologic test varied from 26 % to 100 % depending on the
clinical manifestations in cases of defi'nite LB: EM, 26% (7/27);
neurologic, 74 % (31/42); arthritis, 93 %(13/14); and acrodermatitis
chronica atrophicans, 100 % (10/10).
Fifty-one other sera were also tested at the laboratory of the Depart-
ment of Microbiology of the University of Limburg at Maastricht,
Netherlands. There was good agreement between laboratories (r =
.68; P = .0001).
Statistics. X2 analysis was applied to categorical data. In addi-
tion, a stepwise regression analysis was used to explain the varia-
tion in ELISA results. Included in the regression model as predictors
were age and sex of the orienteers, the number of years practicing
orienteering, the number of hours spent weekly in forests for train-
ing activities, and the number of recalled tick bites.
No. with positive
IgG serology (%)
19 (21.6)
22 08.0)
~J (22.5)
53 (33.1)
64 (33.3)
10 (31.3)
248 (26.1)
88 (9.3)
122 (12.8)
356 (37.5)
160 (16.8)
192 (20.2)
32 (3.4)
950 (100.0)
No. of
participants (%)No. of bites
00 not know
Never bitten
1-5
6-10
11-50
>50
Total
orienteers on both occasions. The participants were encouraged to
discuss any problems associated with answering the questionnaire
with the study team. They were further asked to report health prob-
lems arising during the follow-up period immediately to one of us
(H.E). An English summary of the questions, originally posed in
French and German, is available on request.
If the answers on the questionnaire suggested possible LB (e.g.,
redness of the skin or neurologic or joint symptoms), further infor-
mation was obtained by a telephone interview. Disease features were
defined as probable evidence for LB ifthe history strongly suggested
LB but a physician had not been consulted. Only disease manifesta-
tions confirmed by a physician were considered definite evidence
for LB. Review of the clinical data was done by two of us (H. F.,
M.S.) without access to the serologic results.
A total of 70 patients had seen a physician because of signs or
symptoms compatible with a diagnosis of LB. A letter was sent to
these physicians requesting the precise medical findings and details
regarding diagnosis and effects oftreatment. If, after this procedure,
uncertainty as to the clinical diagnosis still persisted, a telephone
call to the physician was made. Definite diagnoses ofLB were based
on physicians' judgments, but it was accepted that the diagnosis was
established retrospectively. In case of arthritis, other causes (e.g.,
rheumatoid arthritis, ankylosing spondylitis, or reactive arthritis)
had to be very unlikely, at least in retrospect. Neurologic manifesta-
tions were accepted as due to LB only if other explanations were
considered unlikely.
Controls. To assess the specificity of a serologic test for LB, a
reference standard for the absence of the disease and for exposure
to B. burgdorferi is necessary. The diagnosis of LB can be based
on clinical judgment or a specific set of diagnostic criteria, which
allows also defining the absence of disease. However, in countries
such as Switzerland it is impossible to definitely exclude exposure
to B. burgdorferi, even if people deny LB manifestations and do not
recall tick bites. Therefore, two different control groups were in-
cluded in the study.
Sera were obtained from 51 healthy volunteers (blood doriors) who
had spent most of their life at altitudes >1000 m. I. ricinus, the tick
that transmits LB in Europe, is rare at 1000-1500 m and has not
been found at altitudes >1500 m [16]. Of course, these persons some-
times may have visited regions at lower altitudes, but on average
they probably had a lower level of exposure to B. burgdorferi than
did most Swiss people.
Demographic data (age, sex, profession) were not available for
these 51. Therefore, a second control group was used: 50 healthy
individuals, 18 male and 32 female, who lived in the greater Berne
area, which has >200,000 inhabitants. The city is situated at an alti-
tude of 500 m. All gave a negative history for LB and denied tick
bites. None had engaged in orienteering. The mean age (±SD) in
this group was 38.1 ± 15.8 years. One person was employed at a
farm; the others were housewives or worked at an office or in a hos-
pital.
Serology. After centrifugation sera were stored at - 20°C until
testing for antibodies against B. burgdorferi. B. burgdorferi strain
B31 was used as the source of antigen. An ELISA was done to de-
tect IgG antibody to B. burgdorferi. Briefly, the ELISA antigen was
prepared as described by Russell et al. [17]. Included in each run
was one pooled negative control serum and a strongly positive test
serum, which was diluted six times from 1:300 to 1:9600. The curve
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NOTE. Positive cutoff: log dilution of ~3.74. EM = erythema migrans.
Table 2. Definite and probable Lyme borreliosis features related
to results of ELISA anti-Borrelia antibody tests.
Table 3. ELISA IgG anti-Borrelia burgdorferi antibodies in
autumn compared with presence of antibodies in the spring of the
same year.
Autumn
Spring IgG antibody
IgG antibody Positive Negative Total
Positive 153 69 222
Negative 44 489 533
Total 197 558 755
2.07
2.84
2.90
3.01
3.14
3.16
3.54
3.64
3.71
3.76
3.83
4.01
4.05
4.10
4.13
4.16
4.23
4.35
2.66
2.99
3.15
3.24
3.77
3.97
4.03
4.23
4.27
4.29
4.33
ELISA IgGType of borreliosis, symptom(s), year
Definite
Polyarthritis, 1970-1972
Arthritis knee, 1983
EM, 1980
EM, 1976
EM,1985
EM, 1985
Meningitis, 1960
Arthritis, 1978
EM, meningitis, 1983
Meningitis, 1978
Arthritis, 1976
EM, 1985
EM, 1984
Polyarthritis, 1965
EM, 1979
EM, 1976 (penicillin treatment)
EM, 1986
EM,1977
Probable
EM, 1984
Meningitis, 1976
Meningitis, Bell's palsy, 1974
EM, 1975
EM, 1985
EM, 1985
EM, 1978
Arthritis, 1981
EM, 1983
Lymphadenosis cutis benigna, 1982
Arthritis, 1973
Clinical features of LB were also observed among 5 orien-
teers who did not show seroconversion. Three persons had
positive IgG tests before they developed EM. On the other
hand, definite LB features during follow-up were seen in 2
who had negative IgG antibody tests both in the spring and
fall. One of these developed classic EM in the summer. The
other, who had borderline ELISA results on both occasions,
showed an atrophic skin lesion of the trunk due to B. burg-
dorferi. This lesion is known by dermatologists as atropho-
was only modest association between the serologic results and
the number of tick bites recalled.
Prevalence ofpositive ELISA Lyme serology. IgG ELISA
tests could be done for 950 study participants (98.5 %). Of
the orienteers, 248 (26.1%) reacted positively. Of controls,
3.9% (2/51) from high altitudes and 6.0% (3/50) from the
greater Berne area were positive.
Prevalence ofa history ofLyme manifestations related to
Lyme serology. Complete clinical and serologic data were
available for 950 (98.5%); 18 (1.9%) had had definite LB
manifestations (table 2). In another 11, LB could not be
confirmed by a physician, but patients' descriptions of their
findings strongly suggested LB. These 11cases were consid-
ered probable LB. Seven (39 %) of the 18 with definite LB
had had no EM, 5 (28 %) had suffered from arthritis, and 3
(17%) from neurologic manifestations. Therefore, in this high-
risk group the prevalence of a history of clinical LB was 1.9 %
for definite disease (18/950) and 3.1% for definite or probable
disease (29/950). The probable LB cases included 6 who
reported classic EM but did not consult a physician for it.
Clinical manifestations providing definite or probable evi-
dence for LB were related to the results of ELISA antibody
tests (table 2). Among the 18 with a definite history of LB,
ELISA IgG anti-Borrelia antibodies were present in 9 (50%).
Of course, we do not know whether in the past a conversion
from seropositiveto seronegative occurred in the other 9. Only
1 patient had been given antibiotic treatment for LB. How-
ever, we do not know how many patients may have received
such treatment for unrelated health problems.
Incidence study. Altogether, 69 (12.4 %) of 558 par-
ticipants negative for IgG by ELISA in the spring were posi-
tive in the autumn (table 3); 29 of these noticed at least one
tick bite between spring and autumn. The 69 who showed
seroconversion included some borderline cases (figure 1).
Therefore, how much change on the log-dilution scale in the
IgG ELISA technique represents relevant change? To put it
differently, how much change correlates with a fourfold rise
in immunofluorescence titer, which is taken as the usual stan-
dard of clinical significance? In our hands, a decrease in log
dilution of 0.40 roughly corresponds to a fourfold increase
in immunofluorescence titer (unpublished data).
A total of 63 subjects seronegative in the spring had a de-
crease in log dilution of at least 0.40. In 45 of them the au-
tumn sample showed true seroconversion, as the follow-up
log-dilution value was at or below the 3.74cutoff point. There-
fore, 45 (8.1%) of the initially seronegative participants both
showed significant decrease in log-dilution values and passed
the cutoff value of 3.74. In 17 of the other 18, the follow-up
value was between 3.75 and 4.00, that is, close to positivity.
Only one of these 63 subjects who showed significant increase
in specific IgG antibody developed LB manifestations during
the 6 months between sampling: This person developed Bell's
palsy and had an IgG ELISA decrease from 3.99 to 2.62.
JID 1991;163 (February)
Figure 1. Plot of IgG ELISA tests
for anti-Borrelia burgdorferi anti-
bodies in serum samples obtained
in the spring (sample I) and autumn
(sample Il). Cutofffor a positive IgG
ELISA is log dilution ~3.74.
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derma of Pasini and Pierini. All patients were treated with
penicillin.
Thus, in total 6 of 755 orienteers developed definite LB
features in the 6 months between spring and fall. Hence, the
6-month incidence was 0.8% for clinical LB but much higher
(45/558, 8.1%) for inapparent infection.
Regression analysis. Only the number of tick bites and
age contributed significantly to explaining the variation in
ELISA serology; however, the amount of variance was small
(R2 = .03). Gender, the number of years practicing orien-
teering, and the number of hours spent every week in forests
did not contribute significantly.
Discussion
Determining a valid estimate of the prevalence and inci-
dence of a disease requires reliable diagnostic tools. The prob-
lem in defining specificity in an infectious disease such as LB
is that currently no reference standard for the absence of ex-
posure is available. Therefore, in individual cases it is impos-
sible to differentiateasymptomatic (subclinical) infection from
false-positive serology if syphilis or other spirochetoses have
been ruled out. Tominimize this problem we used as one con-
trol group blood donors who, because they lived at high alti-
tudes, supposedly had had low exposure to B. burgdorferi.
The most striking feature from this study is the discrepancy
between the high prevalence and incidence of positive Lyme
serology and the infrequent development of clinically appar-
ent LB. However, in the interpretation of these findings the
possibility of four sources of bias should be considered.
First, our serologic tools could have been too sensitive,
resulting in a high proportion of false-positives. This expla-
nation, however, seems unlikely, since at the chosen cutoff
level the increased prevalence (26.1%) of high antibody titers
occurred exclusively in the orienteers, but not in the controls
(prevalence, 3.9 %-6.0 %). This means that orienteers were
4.4-6.7 times more likely to have positive serologic results.
The low prevalence of positive antibodies in the high-altitude
controls supports a favorable specificity of the test. Also, the
4 %-6% prevalence of antibodies is of the same magnitude
as found in other studies (discussed below). Although the 50
controls from the Berne area denied having had tick bites,
this does not exclude exposure to B. burgdorferi, because in-
fection may have occurred unnoticed. This is also shown in
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table 1, in which 12.8% of those who denied ever being bit-
ten had positive Lyme serology. This raises questions about
the discriminative value of this part of the clinical history as
a diagnostic tool for the diagnosis ofLB and about the useful-
ness of recalled tick bites as a classification or diagnostic
criterion.
Raising the positive cutoff level of 3 (instead of 2) SD above
the mean in the controls would increase the specificity, but
the sensitivity would decrease. This phenomenon might partly
explain why Dattwyler et al. [18] found some patients with
definite LB to have negative serologic tests but at the same
time to show positive stimulation oflymphocytes if challenged
with B. burgdorferi antigen.
Second, LB features may havebeen underreported by orien-
teers. Also, the validity and reliability of the questionnaire
was not assessed beforehand. However, overreporting of such
features of LB as skin lesions, joint problems, or possible neu-
rologic complications seems more likely than underreport-
ing. EM especially may be regarded as a reliable feature,
because it is easily noticed and has characteristics that make
it likely to be recalled by a patient. Typical examples of EM
were shown on a poster to all participants.
Third, interpretation of reported features as compatible with
LB might have been too restrictive. However, even if we were
to accept every reported clinical feature as proof of LB, most
of those with anti-B. burgdorferi antibodies would have to be
classified as having an asymptomatic disease: Only 28 % with
IgG antibodies reported clinical features in the questionnaire.
Therefore, the absence of LB manifestations in most seroposi-
tives is indeed striking.
Fourth, we could have missed recent or unimpressive cases.
The 6-month follow-up study indicated that only 1 (1.6%) of
63 who showed a significant increase in IgG antibodies against
B. burgdorferi developed signs ofLB within the study period.
However, some recently infected people could already have
developed positive serology before the appearance of clinical
manifestations (i.e., further follow-up is indicated). Also, it
is possible we missed some LB cases who had nonspecific
symptoms such as fever, myalgia, or mild arthralgia only [19].
Such features may have passed unnoticed or have been for-
gotten by the orienteers. Nonetheless, based on our findings,
it seems likely that-at least in Switzerland-most people in-
fected with B. burgdorferi do not develop clinical manifesta-
tions of skin, joint, or nervous system. Therefore, in this
respect, LB seems to resemble other infectious diseases as
rubella or toxoplasmosis in which many infected persons do
not develop arthritis or neurological manifestations. It is un-
clear to what extent such complications of the disease are due
to host factors and to geographic differences within strains
of B. burgdorferi. It has been suggested that some strains might
be more pathogenic than others, possibly because of the pres-
ence of certain not-yet-identified plasmids. It is possible that
variation in extrachromosomal DNA accounts for effects that
determine the difference in disease expression among B. burg-
dorferi microorganisms [20]. In general, European isolates
have been more diverse than American isolates [6].
How do our data compare with other reports? Among ru-
ral West Germans, 15.7% of subjects had an immunofluores-
cent antibody IgG titer ~1:128 [21-23], whereas 27% offorest
workers and 46 % of children who had tick bites had IgG titers
~1:64 [24]. In England, positive serology figures ranging from
1% (London) to 7 % (Southampton) were reported [25]. In
the United States, the proportion of controls with positive
Lyme serology in several studies ranged from none to 10%
[10, 14, 17, 26, 27]. In an East Coast community, 4 (3.1%)
of 129 who were followed during the summer season showed
at least fourfold rises in IgG antibody titer, including 2 with-
out clinical LB [14].
The estimated 1:1 ratio of apparent to inapparent infection
in two United States studies contrasts sharply with our results,
which indicate that in Switzerland most infections remain in-
apparent [8, 14, 28] The reason for the discrepancy is un-
clear. Possibly geographic differences in the pathogenicity of
Borrelia strains or in the distribution of pathogenic strains
should be taken into consideration. Therefore, our results may
not necessarily be extrapolated to other countries. Clearly,
more studies are needed. Remarkably, the difference in the
incidence of clinical LB is less striking. Six persons from the
cohort of 755 participants (0.8%) developed LB between spring
and autumn. Assuming that about the same number of cases
could occur within the next half-year leads to an annual inci-
dence of 1'\.112/755 (1.6%). (The assumption that the same num-
ber of cases would occur between autumn and spring may
slightly overestimate the true incidence.) This estimated in-
cidence compares well with estimates in the United States,
which range from 0 to 3.3 % per year for two East Coast
regions well known for the occurrence of LB [8, 14].
What are the implications of the high prevalence of posi-
tive Lyme serology and the low occurrence of clinical dis-
ease? Serologic tests for LB are useful in the absence of EM
or in diagnosis of late manifestations, which cannot be distin-
guished clinically from a variety of other diseases. Certainly,
cautious interpretation of cutoff levels and titers is warranted
[29, 30]. But, can positive tests be taken a step beyond proof
of infection and be used to establish a cause-and-effect rela-
tionship between the infection and clinical manifestations [31]?
Our study strengthens the view that, at least in populations
with a low prevalence of clinical LB and a high prevalence
of asymptomatic positive Lyme serology, diagnostic testing
is of limited value. If, in the absence of other evidence for
LB, the pretest probability of LB is low, serologic testing will
not offer any great advantage. This would be the case in a
patient with unspecified arthritis who gives a negative his-
tory of EM. Indeed, symptoms caused by another disease may
be attributed wrongly to LB [6].
Serologic testing is most useful if the pretest probability
is 1'\.140%-60%, for example, a patient with unspecified ar-
thritis, who does not recall having had EM but has a history
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of meningitis or neuritis of unknown etiology before onset
of joint symptoms [32, 33]. It cannot be emphasized too
strongly that serologic results must be interpreted with cau-
tion; the physician must beware of false-negative and, more
commonly, false-positive results [6]. The decision to treat
should be made with reference to the patient's clinical pre-
sentation and the predictive value of the diagnostic assay [34].
The results of serologic testing should not be relied on as the
sole criterion in making the diagnosis of LB [35].
In conclusion, positive serology for LB was common in
Swiss orienteers but clinical LB occurred infrequently. In such
a setting, serologic diagnostic tests for anti-B. burgdorferi an-
tibodies are of limited value in the absence of sufficient clini-
cal evidence of LB.
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